Latest Whitepapers

High-fidelity affinity chromatography ligands can support more efficient, cost-effective manufacturing, providing superior yield in a single purification step and accelerating drugs to market.

This whitepaper explores how antibody-based affinity chromatography can reduce the number of process steps, improve yield and increase the purity of your biologic products.

The rapid and accurate identification of microbial contaminants is crucial for quality control in pharmaceutical processes and products. However, until recently, testing labs have relied on time-consuming phenotypic approaches to ensure that safety standards are met.

Although there are initiatives to de-risk the drug development process, continually applying the same tools and approaches is unlikely to lead to innovative, first- or best-in-class targets and transformative progress.

Active cell therapy drugs represent the latest in cancer treatment. Of these, chimeric antigen receptor (CAR) cell modalities are considered the most successful.

Rather than choosing between the detail of single-cell RNA sequencing and the in situ capabilities of conventional immunohistochemistry, spatial phenotyping allow you to visualize and quantify dozens of biomarkers in a single tissue sample while maintaining cellular and sub-cellular detail.

Serious infectious disease outbreaks have been an ever-present threat throughout human history and, driven by factors such as increasing globalization, population growth, urbanization and climate change, that threat is increasing.

Flow cytometry has enabled the discovery of varied and nuanced cell types in terms of phenotypic markers and biological functions, but the visible spectrum places limitations on the number of extrinsic parameters that can be assessed.

Traditionally, manual or semi-automated methods using counting chambers or slides are used in cell counting but there is a high degree of variability in this method attributed to operator error.

Cancer immunotherapy, especially the use of immune checkpoint inhibitors, has been successful in improving the treatment landscape of malignancies.